Loading stock data…
TECX
$29.06+1.09 (+3.90%)
Market ClosedLast close May 1
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs).
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tectonic Therapeutic, Inc. in the Healthcare sector is trading at $29.06. The stock is currently 19% below its 52-week high of $36.03, remaining 31.6% above its 200-day moving average. Technical signals show neutral RSI of 44 and bearish MACD signal, explaining why TECX maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 44) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$29.06
Potential Upside
5%
Whystock Fair Value$30.51
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Mean target$77.89+168.0%
Range$60.00 – $101.00
Fundamentals
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$535.13M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-26.25%
Volume
Today's trading volume
115,673
Recent News
Tectonic Therapeutic (NASDAQ:TECX) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Tectonic Therapeutic Spotlights TX2100 in HHT as First-in-Human Phase 1 Dosing Begins
Tectonic Therapeutic (NASDAQ:TECX) used a virtual key opinion leader (KOL) event to outline its strategy for hereditary hemorrhagic telangiectasia (HHT) and highlight early clinical progress for TX2100, an investigational APJ antagonist designed to treat bleeding driven by dysregulated angiogenesis.
Daniel Lochner Bought 70% More Shares In Tectonic Therapeutic
Investors who take an interest in Tectonic Therapeutic, Inc. ( NASDAQ:TECX ) should definitely note that the Chief...
Tectonic Therapeutic (TECX): LifeSci Capital Reiterates Buy Rating
Tectonic Therapeutic, Inc. (NASDAQ:TECX) is one of the Best Micro-Cap Stocks to Invest in According to Analysts. On November 18, LifeSci Capital reiterated a Buy rating on Tectonic Therapeutic, Inc. (NASDAQ:TECX) stock with a price target of $88. Tectonic Therapeutic, Inc. (NASDAQ:TECX) is a biotechnology company that focuses on the discovery and development of therapeutic […]
Bullish Tectonic Therapeutic Insiders Loaded Up On US$61.2m Of Stock
Multiple insiders secured a larger position in Tectonic Therapeutic, Inc. ( NASDAQ:TECX ) shares over the last 12...